The Story: A Supplement Brand Growing at the Speed of Venture, Without Venture’s Price Tag
Nineteen months. That is all it took for IM8 (the AI-native, direct-to-consumer wellness brand co-founded by Danny Yeung and David Beckham) to go from idea to what its parent company, Prenetics Global (NASDAQ: PRE), now calls “the fastest-growing premium supplement brand ever recorded.” By June 2026, the brand was shipping roughly 200,000 servings per day, logging an order every 27 seconds across 43 countries, and delivering a record $17 million in a single month of revenue.
But the more instructive part of the IM8 story is not the growth itself. It is how the growth was financed, and why the decision Yeung faced in mid-2026 stands as one of the cleanest illustrations of the non-dilutive capital thesis in recent memory.
By May 31, 2026, Prenetics held approximately $139.7 million in combined cash, current financial assets, and escrowed consideration, a healthy balance sheet for a brand of its age. The company had even announced a $40 million share repurchase program earlier in the year. This was not a distressed founder reaching for any capital he could find. This was a founder who had proven his unit economics, knew exactly what each dollar of marketing spend returned, and faced a very specific question: how do you pour rocket fuel on a machine with provably positive returns, without handing equity to someone who will want the wheel?
The Decision: Equity Dilution, Balance Sheet Constraint, or a Third Way?
The conventional options in front of any high-growth consumer brand at this stage are well-worn. You can raise a dilutive equity round, a Series B or C that buys you runway but permanently surrenders a piece of every dollar of future enterprise value. Or you can self-fund marketing from operating cash flow, which preserves ownership but caps the pace of growth to whatever cash the business generates in real time. Neither option is wrong. Both involve a material trade-off.
As Prenetics described the strategic rationale in its public filings, management viewed the choice as a structural problem, not merely a funding one. Historically, high-growth consumer businesses scaling customer acquisition had faced a binary choice: raise dilutive equity capital, or hold back on growth to preserve cash reserves. IM8 chose neither.
On July 14, 2026, Prenetics announced that IM8 had closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund (CVF): a non-dilutive facility designed to finance up to 70% of IM8’s global marketing spend, structured entirely around the economics of individual monthly customer cohorts.
The mechanics are worth understanding closely, because they represent a genuinely different instrument from traditional debt or equity:
- No equity, no warrants, no convertibles. The arrangement does not involve the issuance of any equity, warrants, or convertible instruments to General Catalyst, no cap table impact whatsoever.
- No fixed maturity, no covenants. There is no fixed repayment obligation, no maturity date, and no financial covenants tied to consolidated balance sheet performance.
- Cohort-matched repayment. General Catalyst funds up to 70% of each month’s marketing spend. That month’s new customers form a discrete cohort. General Catalyst receives a capped share of revenue from that specific cohort until a fixed return multiple (capped at 1.17×) is recovered. After that, all revenue from those customers permanently reverts to IM8.
- Risk transfer, not risk sharing. If a cohort underperforms, General Catalyst absorbs the loss. There is no recourse to Prenetics’ balance sheet beyond the revenue those customers generate.
General Catalyst’s CVF is not a new instrument (the firm has deployed it across more than 40 companies, including Fivetran and Lemonade) but the IM8 deal represents one of the largest single deployments of the structure to date. In 2025, Grammarly had also secured a $1 billion CVF commitment for its sales and marketing spend under comparable terms.
The Outcome: Every Dollar Already Returned $1.44 in Gross Profit, Before the Billion Deployed
The most striking data point in the entire IM8 announcement was not the size of the facility. It was the unit economics that justified it. Across all mature customer cohorts, every monthly cohort since IM8’s launch through Q1 2026, every $1 invested in customer acquisition had already returned $1.44 in gross profit. And because IM8 sells subscriptions, that figure continues to rise with every passing month as subscribers reorder.
Every single mature customer cohort since IM8’s launch had exceeded the contractual performance thresholds that General Catalyst underwrote in its diligence, a diligence process conducted at the individual transaction level for each cohort. This is not a lender taking a bet on a brand story. It is a capital provider underwriting a proven acquisition engine with granular data.
The financial outcomes speak directly to the equity-preservation thesis:
- Prenetics raised its full-year 2026 IM8 revenue guidance to $210–220 million, its second upward revision of the year, up from a prior range of $190–210 million.
- IM8 is expected to reach $300 million in annualized run-rate revenue by year-end 2026 and deliver in excess of $400 million in full-year 2027 revenue.
- The company’s own cash reserves, roughly $139.7 million, remain available for product innovation, clinical research, and strategic M&A rather than being consumed by a marketing flywheel that can now be self-funding through cohort repayment.
- Shareholders retain 100% of the compounding upside on every customer cohort once General Catalyst’s capped return is satisfied, permanently.
Contrast this with the counterfactual: a $200 million Series C at a compressed 2026 valuation would have diluted existing shareholders by an estimated 20–30%, and that dilution would be permanent, applying to every dollar of the company’s future value, not just the capital deployed for customer acquisition. The CVF structure, by contrast, costs Prenetics a capped 1.17× return on the specific cohorts financed: a defined, finite, self-liquidating cost rather than a permanent tax on enterprise value.
The Lessons: A Framework for Founders Facing the Same Decision
The IM8 story is not universally replicable, and that is precisely what makes it instructive. The CVF structure worked here because of a specific confluence of conditions that founders and operators should use as a diagnostic checklist before pursuing cohort-matched or any non-dilutive CAC financing:
1. Proven, Measurable Unit Economics Are the Prerequisite
General Catalyst did not underwrite a growth narrative. They underwrote transaction-level cohort data. Founders need to be able to demonstrate, with granular historical data, that a dollar of marketing spend produces a reliably positive and measurable return within a defined payback window. IM8’s mature cohorts paid back within approximately three to six months. Without that proof, no capital provider will take on the downside risk this structure requires them to absorb.
2. The Right Instrument Matches the Asset Being Financed
Traditional debt has a fixed repayment schedule regardless of business performance, a structural mismatch with the variable, cohort-driven payback of customer acquisition spend. Equity never expires, which means it is permanently expensive. The CVF model solves for this: repayment matches the economic output of the spend it financed. As General Catalyst has described in its own published writing on the strategy, sales and marketing spend can be treated as a financeable asset, the way equipment financing treats capital equipment.
3. Non-Dilutive Capital Is Not Cheap Capital: It Is Appropriately Priced Capital
The CVF carries a capped return of 1.17×, not trivial. But founders should compare this cost not to venture debt rates or bank loans, but to the true cost of equity dilution compounded over a multi-year growth trajectory. A founder who surrenders 25% at a Series A loses 25% of every dollar of future exit value, not just the capital deployed. The dilution cost compounds; the CVF cost does not.
4. The Broader Market Is Moving This Direction
The IM8 deal is a high-profile instance of a structural shift that is well underway. Revenue-based financing has been growing at over 62% annually, reaching $9.77 billion in market volume in 2025. Venture debt deal volume in 2025 finished 11% higher than 2024. In a VC environment where activity has dropped approximately 35% from its 2021 peak, founders with proven unit economics increasingly have the leverage to demand non-dilutive structures, and providers are building products to meet them.
5. Strength Negotiates Better Terms Than Desperation
One detail in the Prenetics announcement deserves particular emphasis: the company entered the CVF partnership from a position of financial strength, with nearly $140 million on its balance sheet and an active share buyback in progress. This is the counterintuitive truth of non-dilutive financing, the founders who need it least are often the ones who can access it on the best terms, because their cohort data is cleanest and their negotiating position is strongest. Raise capital from strength, not from necessity.
Key Insights
- Cohort-matched CAC financing treats marketing spend as a financeable asset. When repayment is tied to the revenue produced by each specific customer cohort, rather than to a fixed debt schedule, the instrument structurally aligns with how customer acquisition economics actually work.
- The binary choice between equity and cash-constrained growth is no longer the only option. The IM8 / General Catalyst CVF deal is a real-world proof point that a $1 billion growth financing can be structured with zero equity dilution, no fixed maturity, no covenants, and downside risk transferred entirely to the capital provider on underperforming cohorts.
- The permanent cost of equity dilution dwarfs the finite cost of cohort-matched financing. A 25% Series C dilution applies to 100% of future enterprise value, forever. A 1.17× capped return applies only to the cohorts financed and expires the moment that cap is met.
- Unit economics transparency is both the qualification criterion and the negotiating chip. Founders who can present clean, granular, transaction-level cohort data are not just proving creditworthiness; they are demonstrating the same visibility that allows a capital provider to price downside risk confidently enough to absorb it.
- The non-dilutive capital market is institutionalizing rapidly. General Catalyst’s CVF has now been deployed across 40+ companies. Revenue-based financing reached $9.77 billion in market volume in 2025. Founders with predictable acquisition engines are increasingly choosing instruments designed for their specific economic profile rather than defaulting to the equity path.
